Objective To investigate the efficacy and safety of cervical intralymphatic immunotherapy (CILIT) in children with allergic rhinitis (AR).Methods Clinical data of 24 AR children treated with CILIT were studied retrospectively. The nasal symptom score, ocular symptom score, drug score at baseline and one year after CILIT, as well as adverse reactions during treatment were observed and recorded to explore the efficacy and safety of CILIT.Results The total nasal symptom score, ocular symptom score, and drug score at the baseline were (6.00±2.13), (3.29±2.12) and (2.67±1.17) respectively, while those at one year after CILIT were (2.96±2.48), (1.88±1.26), and (1.25±1.19) The differences between the baseline levels and those at one year after CILIT were all statistically significant (all P<0.01). The total effective rate at one year after CILIT was 75%. During the treatment and follow-up period, only 2 of the 24 children had light local adverse reactions without systemic adverse reactions.Conclusion With good effect and safety, CILIT can significantly alleviate the allergic symptoms of AR in children and greatly shorten the immunotherapy cycle.